Innovations for Changing the Face of Women’s Reproductive Health Therapeutics

At ObsEva, our passion and expertise in reproductive health and pregnancy therapeutics is helping millions of women worldwide lead healthier and more fulfilling lives.

Significant Unmet Needs in Reproductive Health

Millions of women worldwide suffer from reproductive health conditions that affect their quality of life or ability to conceive and may lead to complications during pregnancy.

Innovation From Conception to Birth and Beyond

ObsEva is advancing a robust pipeline of novel, orally-administered, clinical-stage compounds in the areas of uterine fibroids, endometriosis, assisted reproductive technology, and preterm labor.

Recent Updates

09 Oct 2018

ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting

Read more
05 Oct 2018

ObsEva SA Announces Phase 3 IMPLANT 2 Clinical Trial Results of Nolasiban in IVF to be Presented at Annual ASRM Meeting Tuesday October 9, 2018

Read more
03 Oct 2018

ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET)

Read more
28 Sep 2018

Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain

Read more